Suppliers and packagers for generic pharmaceutical drug: SETMELANOTIDE ACETATE

SETMELANOTIDE ACETATE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Rhythm	IMCIVREE	setmelanotide acetate	SOLUTION;SUBCUTANEOUS	213793	NDA	Rhythm Pharmaceuticals, Inc	72829-010-01	1 VIAL, MULTI-DOSE in 1 CARTON (72829-010-01) / 1 mL in 1 VIAL, MULTI-DOSE	2020-12-14

SETMELANOTIDE ACETATE Supplier Landscape: Who Makes It, Who Ships Inputs, and What to Source for Scale-Up

Last updated: May 28, 2026

Setmelanotide acetate is sourced through a limited, controlled supply chain dominated by the branded manufacturer and a small number of qualified API and finishing vendors. Buyer access to final drug product supply and drug-substance inputs is typically mediated by regulatory qualification, quality agreements, and NDA-controlled packaging and analytical systems.

Which companies supply setmelanotide acetate API and finished drug product?

Setmelanotide acetate commercial supply is tied to the branded product authorization and its manufacturing network, with upstream drug-substance (API) production and downstream drug-product (formulation and filling) handled by specialized GMP sites. In practice, “supplier” usually means one of three categories: (1) commercial drug-product manufacturer, (2) API maker, and (3) toll manufacturers supporting formulation fill-finish.

Commercial drug-product supply (U.S. and EU)

• The branded product is marketed as IMCIVREE (setmelanotide).
• Commercial supply is routed through the label holder’s GMP manufacturing chain, with drug-product manufacturing and packaging/final release performed at registered sites under the marketing authorization holder’s control.

API supply

• API supply is controlled at the drug-substance GMP stage, with upstream intermediates and final API handled by qualified facilities and governed by change control because setmelanotide is a peptide with tight quality attributes (identity, purity, aggregation profile, and impurities).

Typical qualified “supplier” roles buyers engage

• Marketing authorization holder or its supply chain entity (contracted for drug product)
• API manufacturer (for bulk setmelanotide acetate)
• Contract manufacturing organization (CMO) for formulation and sterile or controlled environment handling
• Packaging and secondary labeling vendor (where the buyer seeks distribution-optimized presentation)

API vs drug product: how buyers contract

• API purchase: requires buyer’s incoming qualification (CoA review, sampling plan, method suitability) and alignment with specification for peptide acetate salt form.
• Drug product sourcing: requires alignment with NDA/marketing authorization label, container closure system, and release testing methods (water content, peptide content, acetic acid counterion presence, related substances).
• Toll fill-finish: used when the buyer needs scale while keeping proprietary formulation and analytical packages under license.

What raw-material and peptide manufacturing inputs are required for setmelanotide acetate supply?

Setmelanotide acetate is a peptide acetate salt. Supplier scope typically includes peptide synthesis reagents and handling of high-purity peptide intermediates.

Input categories

• Solid-phase peptide synthesis (SPPS) materials and resins
• Protected amino acid building blocks and coupling reagents
• Deprotection and cleavage reagents
• Purification solvents and chromatography media
• Salt formation reagents for acetate salt (acetic acid and controlled neutralization steps)
• Sterility assurance consumables for drug product fill-finish (if drug product is manufactured as sterile injectable)

Quality attributes that drive supplier selection

• Identity and sequence confirmation (analytical fingerprinting)
• Impurity and related-substance profiling (process and degradation impurities)
• Peptide purity and aggregation control
• Salt form consistency (acetate counterion and residual solvent limits)
• Endotoxin/bioburden specs for injectable drug product release

How do setmelanotide acetate suppliers handle GMP controls and release testing?

Suppliers for injectable peptide drugs use tightly controlled GMP releases that typically include:

• Full CoA issuance for incoming and outgoing materials
• Batch traceability from API to finished goods
• Stability program execution (real-time and accelerated)
• In-process controls for peptide synthesis and purification steps
• Validation of cleaning and cross-contamination control

Release testing scope commonly includes

• Assay (peptide content)
• Related substances (HPLC/UPLC impurity profiling)
• Identity (chromatographic and/or mass-based)
• Residual solvents and reagents
• Microbial limits and endotoxin testing (drug product)

What distribution and packaging suppliers support IMCIVREE-style product formats?

For branded peptide injectables, distribution “suppliers” usually include:

• Primary packaging (vials or cartridges depending on device configuration)
• Secondary packaging (cartons, leaflets)
• Labeling and distribution-ready kitting
• Cold-chain and temperature-controlled logistics providers where stability requires it

Packaging supplier qualification typically includes

• Container closure compatibility testing
• Extractables/leachables risk assessment
• Visual inspection and labeling verification under GMP

What manufacturing partners are likely to qualify as setmelanotide acetate suppliers?

In competitive branded peptide supply chains, qualifying partners tend to be those with:

• Prior peptide injectable experience
• GMP capability for peptide synthesis purification and salt formation
• Proven fill-finish execution under controlled conditions
• Regulatory-ready quality systems (change control, deviation handling, CAPA discipline)

Common partner models

• Vertical integration (API and drug product in the same controlled network)
• API supplied by a specialist peptide manufacturer, with drug product produced by a fill-finish CMO
• Late-stage packaging and logistics handled by specialized distributors under quality agreements

What supplier constraints create procurement risk for setmelanotide acetate?

Procurement risk is driven by:

• Limited number of peptide-capable GMP sites
• Complex analytical method lock (buyers must accept method variability limits)
• Regulatory change control friction (analytic system and process changes can require comparability and reporting)
• Stability and temperature-handling constraints that limit logistics flexibility

Where risk shows up

• API lead times for peptide synthesis campaigns
• Scheduling of fill-finish slots at limited CMO capacity
• Release testing capacity and method re-validation bottlenecks

Supplier due diligence checklist for setmelanotide acetate

A buyer typically verifies:

• GMP registration status for API and drug product categories
• Demonstrated capability for peptide acetate salt manufacturing
• Spec alignment with setmelanotide acetate acceptance criteria
• Stability and comparability history (especially if using a toll model)
• Audit history and quality agreement readiness
• Capacity and batch scheduling lead times
• Packaging compatibility and label configuration support

Key Takeaways

• Setmelanotide acetate supply is concentrated in a limited network spanning API peptide synthesis and downstream drug-product fill-finish and packaging.
• Supplier selection is driven less by “willingness to supply” and more by peptide-specific GMP capability, salt form control, and regulatory-grade analytical release systems.
• Procurement risk concentrates around peptide synthesis campaigns, fill-finish capacity, and release testing throughput.
• Buyers should treat supplier sourcing as a quality and comparability exercise covering API, drug product, and packaging/labeling under change-controlled quality agreements.

FAQs

1. Can a CMO supply both setmelanotide acetate API and finished IMCIVREE drug product?
   Usually only if it has end-to-end peptide GMP capability plus validated sterile or controlled fill-finish operations and regulatory release testing alignment.

2. What is the main reason acetate-salt peptide supply is harder than small-molecule API?
   Counterion and impurity profiles, aggregation behavior, and sequence-confirmatory analytics create tighter process control requirements.

3. What should buyers require in a setmelanotide acetate quality agreement?
   Batch traceability, CoA format and release specs, deviation/CAPA notification timelines, stability obligations, and change control triggers for process and analytical methods.

4. How do temperature and storage constraints affect setmelanotide acetate logistics suppliers?
   Cold-chain or controlled storage requirements can limit carrier options and create added lead time for distribution-ready goods.

5. What supplier signal indicates readiness for peptide injectable supply?
   A history of comparable peptide injectable manufacture with validated analytical methods and demonstrated stability program performance for similar product matrices.

References

1. APA citation for FDA Orange Book listings and IMCIVREE regulatory status: FDA Orange Book (accessed via FDA’s publication database).